Business · 18/02/2026Updated: 10/16/2026 · 1 min read
FDA Awards Priority Review Voucher to Abeona Therapeutics for ZEVASKYN
Summary
The FDA has issued a priority review voucher to Abeona Therapeutics, Inc. for its rare pediatric disease product ZEVASKYN (prademagene zamikeracel), approved on April 28, 2025.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →